Nephron Research analyst Thomas DeBourcy upgraded CareDx (CDNA) to Buy from Hold with a $28 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx’s HeartCare Study: A Game Changer in Transplant Monitoring?
- CareDx’s ALAMO Study: A Game Changer in Lung Transplant Surveillance?
- CareDx’s ALAMO Study: A New Era in Lung Transplant Surveillance
- CareDx’s HeartCare Study: A Game-Changer in Transplant Surveillance?
- CareDx Stockholders Approve Key Proposals at Annual Meeting